Gilead Sciences (GILD) Tops Q4 EPS by 1c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Gilead Sciences (GILD) PT Raised to $162 at BofA Securities
February 11, 2026 8:36 AM ESTBofA Securities analyst Tim Anderson raised the price target on Gilead Sciences (NASDAQ: GILD) to $162.00 (from $154.00) while maintaining a Buy rating.
The analyst comments "GILD reported strong 4Q product revenues of $7.9bn ahead of Street estimates (BofA: +4%, cons: +4%) driven by demand outperformance from... More
